(Q83389944)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

Integrating pharmacogenetics into gemcitabine dosing--time for a change? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Joseph Ciccolini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Cédric Mercier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Laetitia Dahan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Nicolas André

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

8 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

439-444

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

Population-based differences in treatment outcome following anticancer drug therapies.

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Pharmacogenomics: the promise of personalized medicine for CNS disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Pharmacogenetics and pharmacogenomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Now's the time to find biomarkers on purpose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Germline genetic variation, cancer outcome, and pharmacogenetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Clinical pharmacology and pharmacogenetics of gemcitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a Children's Oncology Group Report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Phase II study of gemcitabine in children with relapsed leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Survival prediction for pancreatic cancer patients receiving gemcitabine treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Cellular pharmacology of gemcitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Drug penetration in solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Drug resistance and the solid tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Identification of a predictive biomarker for hematologic toxicities of gemcitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Metronomic chemotherapy: new rationale for new directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Should DPD analysis be required prior to prescribing fluoropyrimidines?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.1

Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.

31 March 2020

1 reference

12 December 2020

K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer.

1 reference

12 December 2020

Review of recent studies on resistance to cytotoxic deoxynucleoside analogues

1 reference

12 December 2020

Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with co

1 reference

12 December 2020

HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients

1 reference

12 December 2020

Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCLINONC.2011.1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21304503%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference